Half Year Results 

ReNeuron widens clinical trials

ReNeuron widens clinical trials

Biotech stocks such as ReNeuron (RENE) should sit at the outer edge of risk profiles, with the prospect of highly promising technologies tempered by uncertainties linked to the funding imperative.

To continue reading, subscribe today

and enjoy unlimited access to the following:

  • Tips of the Week
  • Funds coverage
  • Weekly features on big investment themes
  • Trading ideas
  • Comprehensive companies coverage
  • Economic analysis
Subscribe
Subscribe to Investors Chronicle

Subscribe today

Full access for just £3.37 a week:

• Tips and recommendations - to beat the market 
• Portfolio clinic & Mr Bearbull - build a well-planned portfolio 
• Expert tools - track and manage investments effortlessly
• Plus free delivery to your home or office

Subscribe Now